Streetbeat News

Analyst Ratings

AZN

BGNE

JNJ

JMP Securities initiated coverage on BeiGene Ltd (NASDAQ:BGNE), highlighting its flagship drug Brukinsa as a potential market leader in the BTK inhibitor sector. Analyst Reni Benjamin projects Brukinsa to capture 55% of the market by 2031, with significant revenue growth expected. Despite challenges in the Chinese market, BeiGene's strong sales force has driven substantial revenue growth.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 7:20 pm

CPAY

Jefferies analyst Trevor Williams maintains a Buy rating on Corpay (NYSE:CPAY) and raises the price target from $350 to $375.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:20 pm

CUBE

Jefferies analyst Jonathan Petersen maintains a Buy rating on CubeSmart and raises the price target from $53 to $62.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:10 pm

NSA

Jefferies analyst Jonathan Petersen has maintained a Buy rating on National Storage (NYSE:NSA) and raised the price target from $47 to $54.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:05 pm

PSA

Jefferies analyst Jonathan Petersen maintains a Buy rating on Public Storage (NYSE:PSA) and raises the price target from $360 to $422.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 7:03 pm

ZVRA

Canaccord Genuity has maintained its Buy rating on Zevra Therapeutics but lowered the price target from $24 to $22.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 6:57 pm

VFC

Barclays analyst Adrienne Yih upgraded V.F. Corporation (NYSE:VFC) from Equal-Weight to Overweight, raising the price target from $19 to $22. The analyst expects gradual improvements in V.F. Corp's fundamentals over the next four to six quarters, with early signs of product and brand improvements. Despite near-term uncertainties, there is optimism about sales growth at Vans and gross margin expectations. The company is also focusing on debt reduction and leadership changes to stabilize and revitalize the business.

Portfolio Pulse from Nabaparna Bhattacharya

September 18, 2024 | 6:47 pm

INCY

NVS

Truist Securities downgraded Incyte Corporation (NASDAQ:INCY) from Buy to Hold, citing intense competition and the approaching patent loss of its top-selling drug, Jakafi, in 2028. The analyst lowered the price target to $74 from $83. Incyte's pipeline in immunology, inflammation, and oncology is crucial to offset expected revenue declines due to generic competition. Key upcoming data for Povorcitinib and Zilurgisertib will influence stock performance.

Portfolio Pulse from Vandana Singh

September 18, 2024 | 6:44 pm

CRVO

Chardan Capital has initiated coverage on CervoMed (NASDAQ:CRVO) with a Buy rating and set a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 6:38 pm

ARTY

IDGT

SMCI

Needham analyst Quinn Bolton initiated coverage on Super Micro Computer Inc (SMCI) with a Buy rating and a $600 price target, citing margin recovery and AI infrastructure growth. The stock reflects internal control risks, and Super Micro is expanding manufacturing capacity. Investors can also gain exposure through ETFs ARTY and IDGT.

Portfolio Pulse from Anusuya Lahiri

September 18, 2024 | 6:37 pm